by Team Small News | Apr 1, 2025 | Glenmark, Pharma
A UK High Court Judge, Michael Tappin, has rejected a request by AstraZeneca (AZ) and AstraZeneca UK Ltd. for an interim injunction to block Glenmark Pharmaceuticals Europe from launching a generic version of AZ’s diabetes drug, Forxiga. The generic version,... by Team Small News | Mar 26, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Ltd., a leading research-led, global pharmaceutical company, has partnered with Health Futures Foundation, Inc. (HFI) and the Municipality of Malinao to launch a comprehensive initiative to improve nutrition among children and... by Team Small News | Mar 25, 2025 | Glenmark, Pharma
Glenmark has received FDA clearance for its generic version of Alcon’s Pataday Once Daily Relief Ophthalmic Solution, olopatadine hydrochloride ophthalmic solution 0.2% over-the-counter (OTC). This generic medication will be distributed in the US by Glenmark... by Team Small News | Mar 24, 2025 | Glenmark, Pharma
Glenmark Pharma has announced that its US subsidiary, Glenmark Therapeutics Inc., has received approval from the US Food and Drug Administration (USFDA) for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC). This approval allows Glenmark to market the... by Team Small News | Mar 15, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. The company has introduced three treatment options: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg),... by Team Small News | Mar 14, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Ltd. has launched its new product range, Glempa, in India. The range consists of Empagliflozin, a widely recognized SGLT2 inhibitor, in three forms: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg), and...